Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 8, 2026International Journal of Molecular SciencesOpen Access

Dystroglycan signaling emerges as a key factor in cardiac remodeling and fibrosis in acquired HFrEF.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

While the role of dystroglycan signaling is well established in inherited disorders such as Duchenne muscular dystrophy, it is less studied in acquired HFrEF.

Design

Review

Key result

Dystroglycan signaling, essential for sarcolemma stability, is emerging as a key factor in cardiac remodeling and fibrosis in acquired heart failure with reduced ejection fraction.

Authors

BPBhola Shankar PradhanMMMichał Ma̧czewski

Discussion

Loading...

Member takes

Overview

Dystroglycan modulation should not yet inform HFrEF care; extends its role from inherited dystrophies but remains hypothesis-generating.

Key Points

  • To review the signaling mechanisms of dystroglycan in cardiac muscle and evaluate its emerging roles in cardiac remodeling, fibrosis, and acquired heart failure with reduced ejection fraction.
  • Narrative synthesis of cellular and molecular literature regarding dystrophin–glycoprotein complex function in healthy myocardium versus diseased states.
  • Comparative analysis of dystroglycan pathway signaling in inherited muscle dystrophies and acquired heart failure.
  • Dystroglycan maintains cardiomyocyte sarcolemmal integrity, mediates mechanotransduction, coordinates force transmission, and regulates intracellular calcium handling.
  • Perturbations and structural remodeling of dystroglycan complexes are linked to cardiomyocyte death, adverse ventricular remodeling, and progressive myocardial fibrosis in heart failure with reduced ejection fraction.

PICO

P
Population
Heart failure with reduced ejection fraction (HFrEF)
E
Exposure / Comparator
Dystroglycan signaling

Dystroglycan remodeling may play a significant role in the pathophysiology of acquired HFrEF, extending its known importance beyond inherited muscular dystrophies.

Cite This Study

Pradhan et al. (2026) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Dystroglycan signaling was evaluated. Dystroglycan signaling, essential for sarcolemma stability, is emerging as a key factor in cardiac remodeling and fibrosis in acquired heart failure with reduced ejection fraction.

synapsesocial.com/papers/6a9fd79b58e84d0ff5b466bfhttps://doi.org/10.3390/ijms27177948
View Full Paper
Ask AI
Bookmark
Share